Regenxbio Inc (RGNX)
Net profit margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -263,494 | -260,540 | -274,156 | -270,274 | -280,321 | 73,637 | 90,716 | 101,256 | 127,840 | -212,424 | -145,228 | -121,351 | -111,250 | -91,473 | -134,848 | -102,543 | -94,733 | -63,963 | -48,581 | -36,530 |
| Revenue (ttm) | US$ in thousands | 85,585 | 89,565 | 82,833 | 89,765 | 89,470 | 395,745 | 424,505 | 432,813 | 446,605 | 134,740 | 275,433 | 273,347 | 271,089 | 261,412 | 95,283 | 71,153 | 44,415 | 73,424 | 54,848 | 86,998 |
| Net profit margin | -307.87% | -290.89% | -330.97% | -301.09% | -313.31% | 18.61% | 21.37% | 23.39% | 28.62% | -157.65% | -52.73% | -44.39% | -41.04% | -34.99% | -141.52% | -144.12% | -213.29% | -87.11% | -88.57% | -41.99% |
December 31, 2023 calculation
Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $-263,494K ÷ $85,585K
= -307.87%
The net profit margin for Regenxbio Inc has shown significant fluctuations over the past eight quarters. In the most recent quarter of Q4 2023, the company recorded a remarkably low net profit margin of -291.99%, indicating a substantial loss compared to its revenue. This downward trend in profitability is consistent with the previous quarters in 2023, where net profit margins ranged from -246.50% to -282.72%.
It is notable that in contrast to the challenging performance in 2023, the company achieved positive net profit margins in the quarters of Q3 and Q2 in 2022, with figures of 15.34% and 18.73% respectively. However, net profitability declined in Q1 2022 to 21.38%.
The negative net profit margins in the recent quarters suggest that the company may be facing difficulties in generating profits relative to its revenue. The varying levels of profitability indicate fluctuations in the company's ability to control costs and manage its operations efficiently. This inconsistency in the net profit margin performance underscores the importance for Regenxbio Inc to closely monitor its expenses and revenue generation strategies in order to improve profitability and financial stability in the future.
Peer comparison
Dec 31, 2023